Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs Inc is well-positioned for growth in the biotechnology sector, particularly through its innovative product pipeline that includes the first-in-class SL-325 antibody aimed at treating inflammatory bowel disease (IBD) and other inflammatory conditions. The increasing adoption of biologics in the treatment of ulcerative colitis (UC) and Crohn's disease (CD)—with usage rates rising significantly from 2007 to 2015—indicates a growing market that Shattuck Labs aims to penetrate with its cutting-edge therapies. Additionally, the company's conservative sales growth estimates for SL-325 reflect a solid foundation for future revenue generation, underpinned by a projected robust market share increase for effective agents in the therapeutic landscape.

Bears say

Shattuck Labs Inc faces significant challenges in the development of its lead programs, particularly the SL-325 and SL-425 candidates, as there are concerns regarding their potential efficacy, immunogenicity, and safety, which could hinder their market uptake. Furthermore, the biotechnology company operates in an environment where market growth and the adoption of advanced therapies for inflammatory bowel disease are consistently underestimated, complicating its revenue outlook. Additionally, the increasing utilization of existing biologics suggests a competitive landscape that may further limit Shattuck Labs’s ability to capture market share, casting doubt on the commercial viability of its drug candidates.

Shattuck Labs (STTK) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 5 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.